Drug intelligence / Profile preview

infanrix-ipv+hib + prevenar

Development stage: Unknown
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

A combination of two separate vaccines that are commonly administered together in childhood immunization schedules. **Infanrix-IPV+Hib** is a combined vaccine that protects against five diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), and Haemophilus influenzae type b (Hib) disease. It contains: - Diphtheria toxoid: not less than 30 International Units (IU) - Tetanus toxoid: not less than 40 International Units (IU) - Pertussis antigens: - Pertussis toxoid (PT): 25 micrograms - Filamentous haemagglutinin (FHA): 25 micrograms - Pertactin (PRN): 8 micrograms - Poliovirus (inactivated): - Type 1 (Mahoney strain): 40 D-antigen units - Type 2 (MEF-1 strain): 8 D-antigen units - Type 3 (Saukett strain): 32 D-antigen units - Haemophilus influenzae type b polysaccharide (PRP): 10 micrograms conjugated to tetanus toxoid as carrier protein (approximately 25 micrograms) The vaccine is manufactured by GlaxoSmithKline (GSK). **Prevenar (Pneumococcal Conjugate Vaccine)** is a pneumococcal conjugate vaccine that protects against Streptococcus pneumoniae infections. The search results indicate it contains 0.125 milligrams of aluminum as an adjuvant. These vaccines are often administered together as part of childhood immunization schedules, though as separate injections at different sites.

Brand names: Infanrix-IPV+Hib + Prevenar

Beyond the preview

Go deeper on infanrix-ipv+hib + prevenar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on infanrix-ipv+hib + prevenar.

Explore the full profile